The short answer: do statins prevent Alzheimer’s?
No, not proven. A large study published on 6 October 2026 in Frontiers in Aging Neuroscience followed 502,401 UK Biobank participants for a median of 9.24 years and found that people taking statins had about a 28 percent lower risk of developing Alzheimer’s disease than people not taking them.
But there is a catch that changes everything. The researchers observed people; they did not assign them to take statins or not. That makes this an association, not proof of cause and effect. Statins may protect the brain, or statin users may simply differ from non-users in ways the study could not fully measure.
If you take statins for cholesterol, this is reassuring. If you do not take statins, this study alone is not a reason to start.
What the UK Biobank study actually found
The UK Biobank is one of the largest health research resources in the world. Between 2006 and 2010 it recruited around half a million adults aged 40 to 69 across England, Scotland and Wales, and has tracked their health ever since.
For this study, the researchers included 502,401 participants who did not have Alzheimer’s at the start. Over a median follow-up of 9.24 years, they recorded 2,627 new cases of dementia, including 975 cases of Alzheimer’s disease.
People were classed as statin users if their records showed they took one of five cholesterol-lowering drugs, atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin, across the study period. Simvastatin was by far the most commonly used. People who took other medications or had never been exposed to any medication were classed as non-users.
After adjusting for age, sex, education, lifestyle and other medications, the headline result was a hazard ratio of 0.72 with a 95 percent confidence interval of 0.52 to 0.98. In plain language, that means statin users had roughly 28 percent lower risk of a new Alzheimer’s diagnosis, and the result reached statistical significance, though only just.
Two extra findings strengthened the picture. First, the result held up after propensity score matching, a technique that pairs statin users with similar non-users to reduce the bias that comes from doctors prescribing statins to particular kinds of patients. Second, among participants aged 65 and over, statin users performed better on cognitive tests than non-users.
Also reassuring for the result’s stability: taking blood pressure or diabetes medicines alongside statins did not significantly change the apparent protective effect.
How big is the effect, really?
A 28 percent lower risk sounds impressive, but the numbers underneath deserve a closer look.
The confidence interval runs from 0.52 to 0.98. The upper end sits very close to 1.0, which is the point of no effect. The authors themselves describe the finding as reaching only “marginal statistical significance” in the full analysis. When the researchers split the data into an 80 percent training group and a 20 percent validation group, the same pattern appeared but no longer reached statistical significance in either half on its own.
That does not mean the result is wrong. It means the signal is modest and the data are stretched thin, with only 975 Alzheimer’s cases among half a million people. Honest science reports exactly this kind of nuance, and the authors do: they describe a “modest protective association” rather than a breakthrough.
Why scientists cannot call this proof
This is the part that matters most, and it is the part the study authors state clearly.
Observational studies are vulnerable to confounders: differences between statin users and non-users that have nothing to do with the drug. The authors name two in particular. Confounding by indication means doctors prescribe statins to people with higher cardiovascular risk, who may differ in brain health for other reasons. The healthy user effect means people who take their medicines faithfully also tend to do other health-promoting things, like eating better or seeing doctors more often. The authors write that their findings “may be influenced by residual confounding, including confounding by indication, despite our efforts to adjust for measured covariates.”
The wider evidence is also mixed. Systematic reviews and meta-analyses of randomised controlled trials report that statins do not harm cognition, but have not conclusively demonstrated a protective effect against the onset of Alzheimer’s. Some observational studies agree with this new paper; at least one found no association at all. When the evidence looks like this, one large study does not settle the question, no matter how big the cohort.
It is also worth knowing that Alzheimer’s diagnoses in this study came from an algorithm combining hospital records, GP records, death registries and self-reports, without confirmation by brain scans or spinal fluid tests. In a study this size, some diagnoses will have been missed or misclassified. The authors flag this openly.
What statins do in the body, and why anyone looked at the brain
Statins are the most widely prescribed cholesterol-lowering medicines in the world, taken mainly to reduce the risk of heart attacks and strokes. But researchers have long wondered whether they might also protect the brain, for several plausible reasons.
Beyond lowering cholesterol, statins have anti-inflammatory and anti-clotting effects, influence how proteins clump together, and affect insulin signalling, all processes that matter in neurodegeneration. Cholesterol balance in the brain is tightly regulated, and the paper notes that high cholesterol in middle age is associated with later cognitive decline and Alzheimer’s risk.
There is a second, more mundane reason to care. Regulators including the US Food and Drug Administration have warned about possible non-serious and reversible cognitive side effects of statins, such as temporary memory problems. A study showing either harm or protection from the same drug class deserves attention precisely because millions of people take these medicines every day.
Should you start statins to protect your brain?
No. Nothing in this study suggests that. Statins are prescription medicines with real benefits and real side effects, and the decision to take them is about your cholesterol and your cardiovascular risk, made with your doctor.
If you already take a statin, this study is one more reason not to worry about it harming your brain, and possibly a small reason to feel good about it. If you have concerns about memory while taking statins, raise them with your GP rather than stopping on your own, since stopping a cholesterol medicine carries its own well-established risks.
The authors’ own conclusion is careful: statin use was “associated with a modestly lower risk” of Alzheimer’s and slower cognitive decline, and the findings mainly underline the importance of identifying people at risk. Association, modest, and more research needed: that is the honest verdict.
Frequently asked questions
Do statins prevent Alzheimer’s?
Not proven. One large UK Biobank study found statin users had about 28 percent lower risk of developing Alzheimer’s, but it was an observational study and cannot establish cause and effect. Randomised trials have not confirmed a protective effect.
Do all statins protect the brain equally?
This study could not answer that. Simvastatin was by far the most commonly used statin in the cohort, so the researchers did not compare individual statins. Whether some statins cross into the brain more effectively than others remains an open question.
Do statins cause memory problems?
Regulators have warned about possible non-serious, reversible cognitive side effects such as temporary memory lapses. Systematic reviews of trials have not found that statins damage cognition overall. If you notice memory changes on a statin, talk to your GP rather than stopping the medicine.
Should I ask my doctor for statins to lower my dementia risk?
Current evidence does not support starting statins for brain protection alone. The decision to take a statin should be based on your cardiovascular risk. Discuss any concerns with your GP.
What did the UK Biobank study find, exactly?
Among 502,401 participants followed for a median of 9.24 years, 975 developed Alzheimer’s. Statin use was associated with a hazard ratio of 0.72 (95% CI 0.52 to 0.98), meaning roughly 28 percent lower risk, consistent after propensity score matching. Statin users over 65 also performed better on cognitive tests.
Keep reading
- What Are the Symptoms of High Blood Pressure? What 1.4 Million Health Records Revealed
- How Much Deep Sleep Do You Need? What 95,000 Sleep Trackers Say
- Can You Reverse Prediabetes? The 25 Percent Finding That Changes the Advice
Source: Association of statin use with reduced risk of Alzheimer’s disease: findings in UK Biobank, Frontiers in Aging Neuroscience, 6 October 2026. Read the full paper.